The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity

被引:156
作者
James, RW [1 ]
Deakin, SP [1 ]
机构
[1] Univ Hosp Geneva, Fac Med, Div Endocrinol Diabet & Nutr, Clin Diabet Unit, CH-1211 Geneva 14, Switzerland
关键词
free radicals;
D O I
10.1016/j.freeradbiomed.2004.08.012
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The association of paraoxonase-1 (PON1) with high-density lipoproteins (HI)L) is a prerequisite for maintaining normal serum activity of the enzyme. The lipoprotein furnishes an amphipathic environment to shield the hydrophobic, N-terminal region of the enzyme, and such an environment may also be necessary for interaction of PON1 with its substrates. HDL provides the optimal physiological acceptor complex, in terms of both stimulating PON1 secretion and stabilizing the secreted peptide. Lipid and peptide components of HDL contribute to these effects, such that modulating HDL composition influences PON1 activity and function. In this context, understanding how PON1 associates with HDL, what governs the association, and the mechanism by which the PON1-HDL complex exerts its antioxidant function is of particular physiological relevance. Moreover, HDL is subject to substantial compositional variations under both normal and pathological metabolic conditions. It has implications for the influence of the enzyme on cardiovascular risk, as normal enzyme activity may not correlate with optimal functional (antioxidant) efficiency. We review evidence that HDL lipid and protein components interact to promote PON1 secretion and maintain serum enzyme activity. Emerging data on how the enzyme associates with HDL are discussed, and the consequences for PON1 function of modifications to HDL are outlined. Finally, we highlight questions concerning the HDL-PON1 association that remain unanswered but are of particular importance in defining PON1 efficiency. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:1986 / 1994
页数:9
相关论文
共 57 条
[1]   Identification of scavenger receptor SR-BI as a high density lipoprotein receptor [J].
Acton, S ;
Rigotti, A ;
Landschulz, KT ;
Xu, SZ ;
Hobbs, HH ;
Krieger, M .
SCIENCE, 1996, 271 (5248) :518-520
[2]  
ADKINS S, 1993, AM J HUM GENET, V52, P598
[3]   Apolipoprotein A-I promotes the formation of phosphatidylcholine core aldehydes that are hydrolyzed by paraoxonase (PON-1) during high density lipoprotein oxidation with a peroxynitrite donor [J].
Ahmed, Z ;
Ravandi, A ;
Maguire, GF ;
Emili, A ;
Draganov, D ;
La Du, BN ;
Kuksis, A ;
Connelly, PW .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (27) :24473-24481
[4]   The concept of apolipoprotein-defined lipoprotein families and its clinical significance [J].
Petar Alaupovic .
Current Atherosclerosis Reports, 2003, 5 (6) :459-467
[5]   Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions - PON1 esterase and peroxidase-like activities [J].
Aviram, M ;
Hardak, E ;
Vaya, J ;
Mahmood, S ;
Milo, S ;
Hoffman, A ;
Billicke, S ;
Draganov, D ;
Rosenblat, M .
CIRCULATION, 2000, 101 (21) :2510-2517
[6]   IDENTIFICATION OF A DISTINCT HUMAN HIGH-DENSITY-LIPOPROTEIN SUBSPECIES DEFINED BY A LIPOPROTEIN-ASSOCIATED PROTEIN, K-45 - IDENTITY OF K-45 WITH PARAOXONASE [J].
BLATTER, MC ;
JAMES, RW ;
MESSMER, S ;
BARJA, F ;
POMETTA, D .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1993, 211 (03) :871-879
[7]  
Boisfer E, 2002, J LIPID RES, V43, P732
[8]   HIGH-DENSITY-LIPOPROTEIN IS THE MAJOR CARRIER OF LIPID HYDROPEROXIDES IN HUMAN BLOOD-PLASMA FROM FASTING DONORS [J].
BOWRY, VW ;
STANLEY, KK ;
STOCKER, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (21) :10316-10320
[9]   Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression [J].
Brophy, VH ;
Jampsa, RL ;
Clendenning, JB ;
McKinstry, LA ;
Jarvik, GP ;
Furlong, CE .
AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 68 (06) :1428-1436
[10]   Polymorphisms in the human paraoxonase (PON1) promoter [J].
Brophy, VH ;
Hastings, MD ;
Clendenning, JB ;
Richter, RJ ;
Jarvik, GP ;
Furlong, CE .
PHARMACOGENETICS, 2001, 11 (01) :77-84